Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anitocabtagene autoleucel - Arcellx

Next Previous
X
Search
Drug Profile

Anitocabtagene autoleucel - Arcellx

Alternative Names: Anito-cel; Anti B cell maturation antigen-receptor complex T cell therapy - Arcellx; Anti BCMA directed ARC T cell therapy - Arcellx; BCMA-targeted cell therapy - Arcellx; CAR-T ddBCMA; Kite-772

Latest Information Update: 24 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arcellx
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Multiple myeloma
  • Phase I Myasthenia gravis

Most Recent Events

  • 13 Jan 2025 Phase-I clinical trials in Myasthenia gravis in USA (IV) (NCT06626919)
  • 08 Dec 2024 Efficacy and adverse events data from a phase iMMagine-1 trial in Multiple myeloma released by Arcellx
  • 07 Dec 2024 Efficacy and adverse events data from a phase phase II iMMagine-1 trial in Multiple myeloma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top